Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310722 | 1.00 | NNMT (0.46) | NNMTPDGFRBPDGFRAMEN1ALDH1A1 | |
| SCHEMBL30310720 | 0.86 | PIN1 (0.47) | PDGFRBPDGFRAMEN1ALDH1A1CYP1A2 | |
| SCHEMBL2107849 | 0.86 | PIN1 (0.47) | PDGFRBPDGFRAMEN1ALDH1A1CYP1A2 | |
| SCHEMBL3754482 | 0.85 | XDH (0.47) | PDGFRBPDGFRAALDH1A1CYP1A2SIRT2 | |
| SCHEMBL24112624 | 0.82 | ALOX15 (0.47) | PDGFRBPDGFRAALDH1A1MAPTSIRT2 | |
| SCHEMBL2109109 | 0.80 | RAB9A (0.60) | MEN1ALDH1A1MAPTKMT2APDE10A | |
| SCHEMBL5716780 | 0.80 | MEN1 (0.60) | PDGFRBPDGFRAMEN1ALDH1A1CYP1A2 | |
| SCHEMBL24019773 | 0.80 | ALOX15 (0.51) | MEN1ALDH1A1MAPTKMT2ASIRT2 | |
| SCHEMBL30983210 | 0.78 | F7 (0.41) | PDGFRBALDH1A1MAPTCYP2C19MMP2 | |
| SCHEMBL30983212 | 0.78 | F7 (0.41) | PDGFRBALDH1A1MAPTCYP2C19MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626027-B2 | Substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase Iε | AVENTIS PHARMACEUTICALS INC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1747220-B1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMA INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | AVENTIS PHARMACEUTICALS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7402672-B2 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1747220-A1 | SUBSTITUTED 1H-PYRROLO 3,2-B, 3,2-C, AND 2,3-C¨PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | Aventis Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005061498-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | CSNK1E, CSNK1G3, CSNK2A3 | NNMT 1961/4885PDGFRB 2301/4885PDGFRA 2467/4885 |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | CSNK2A3, PACSIN2, CSNK1G3 | NNMT 2982/4885PDGFRB 2385/4885PDGFRA 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.